SK143199A3 - Pharmaceutical composition for treating sleep apnea, lung alveolar surfactant, phospholipid, use thereof and device for treating sleep apnea - Google Patents

Pharmaceutical composition for treating sleep apnea, lung alveolar surfactant, phospholipid, use thereof and device for treating sleep apnea Download PDF

Info

Publication number: SK143199A3
Authority: SK; Slovakia
Prior art keywords: sleep apnea; surfactant; phospholipid; treating sleep; apnea
Prior art date: 1997-04-16

Application number

SK1431-99A

Other languages

English (en)

Slovak (sk)

Inventor

Keith C Meyer

Safwan M Badr

Original Assignee

Wisconsin Alumni Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-16

Filing date

1998-04-16

Publication date

2001-01-18

1998-04-16 Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found

2001-01-18 Publication of SK143199A3 publication Critical patent/SK143199A3/sk

Links

239000003580 lung surfactant Substances 0.000 title claims abstract description 11
201000002859 sleep apnea Diseases 0.000 title claims description 35
150000003904 phospholipids Chemical class 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title 1
238000003860 storage Methods 0.000 claims abstract description 3
239000004094 surface-active agent Substances 0.000 claims description 33
239000000203 mixture Substances 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 12
210000003800 pharynx Anatomy 0.000 claims description 11
239000000443 aerosol Substances 0.000 claims description 8
108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims description 7
102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
230000007935 neutral effect Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims description 4
102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
239000011248 coating agent Substances 0.000 claims description 3
238000000576 coating method Methods 0.000 claims description 3
230000002685 pulmonary effect Effects 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 claims description 2
102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
229920006395 saturated elastomer Polymers 0.000 claims 2
101710098761 Protein alpha-1 Proteins 0.000 claims 1
102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229940126523 co-drug Drugs 0.000 claims 1
238000000151 deposition Methods 0.000 claims 1
150000002632 lipids Chemical class 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
235000004252 protein component Nutrition 0.000 claims 1
238000007873 sieving Methods 0.000 claims 1
229910000077 silane Inorganic materials 0.000 claims 1
208000008784 apnea Diseases 0.000 abstract description 17
206010021079 Hypopnoea Diseases 0.000 abstract description 13
230000002829 reductive effect Effects 0.000 abstract description 7
229940066294 lung surfactant Drugs 0.000 abstract description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
229910052760 oxygen Inorganic materials 0.000 abstract description 3
239000001301 oxygen Substances 0.000 abstract description 3
208000019116 sleep disease Diseases 0.000 abstract description 3
230000007170 pathology Effects 0.000 abstract 1
208000022925 sleep disturbance Diseases 0.000 abstract 1
206010041235 Snoring Diseases 0.000 description 23
238000000034 method Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
235000003403 Limnocharis flava Nutrition 0.000 description 4
244000278243 Limnocharis flava Species 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
208000023504 respiratory system disease Diseases 0.000 description 4
230000008667 sleep stage Effects 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
102000006410 Apoproteins Human genes 0.000 description 3
108010083590 Apoproteins Proteins 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000000147 hypnotic effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000009434 installation Methods 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
229910052715 tantalum Inorganic materials 0.000 description 3
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
208000037849 arterial hypertension Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
229940063649 survanta Drugs 0.000 description 2
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
229960004224 tyloxapol Drugs 0.000 description 2
229920001664 tyloxapol Polymers 0.000 description 2
210000002396 uvula Anatomy 0.000 description 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
YBJCDTIWNDBNTM-UHFFFAOYSA-N 1-methylsulfonylethane Chemical compound CCS(C)(=O)=O YBJCDTIWNDBNTM-UHFFFAOYSA-N 0.000 description 1
PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
VPIDXLJVGVBFOW-UHFFFAOYSA-N C=1C=[C-]PC=1 Chemical compound C=1C=[C-]PC=1 VPIDXLJVGVBFOW-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
241001669679 Eleotris Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
235000002873 Gentiana lutea Nutrition 0.000 description 1
240000003409 Gentiana lutea Species 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
208000019914 Mental Fatigue Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
241001147384 Potos Species 0.000 description 1
101100194325 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) REI1 gene Proteins 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940092456 curosurf Drugs 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
229960003528 flurazepam Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000008821 health effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
229940026289 infasurf Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229940016409 methylsulfonylmethane Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
210000001184 pharyngeal muscle Anatomy 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
238000010321 sleep therapy Methods 0.000 description 1
208000020685 sleep-wake disease Diseases 0.000 description 1
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Zoology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Nutrition Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Marine Sciences & Fisheries (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

SK1431-99A 1997-04-16 1998-04-16 Pharmaceutical composition for treating sleep apnea, lung alveolar surfactant, phospholipid, use thereof and device for treating sleep apnea SK143199A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/834,369 US5958902A (en)	1997-04-16	1997-04-16	Method and composition for treating sleep apnea
PCT/US1998/007735 WO1998046245A1 (en)	1997-04-16	1998-04-16	Method and composition for treating sleep apnea

Publications (1)

Publication Number	Publication Date
SK143199A3 true SK143199A3 (en)	2001-01-18

Family

ID=25266775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1431-99A SK143199A3 (en)	1997-04-16	1998-04-16	Pharmaceutical composition for treating sleep apnea, lung alveolar surfactant, phospholipid, use thereof and device for treating sleep apnea

Country Status (23)

Country	Link
US (3)	US5958902A (ja)
EP (1)	EP1009411B1 (ja)
JP (1)	JP2001507364A (ja)
KR (1)	KR100381643B1 (ja)
CN (1)	CN1252727A (ja)
AR (1)	AR012221A1 (ja)
AT (1)	ATE298241T1 (ja)
AU (1)	AU722866B2 (ja)
BG (1)	BG103800A (ja)
BR (1)	BR9809090A (ja)
CA (1)	CA2285574C (ja)
CO (1)	CO4940399A1 (ja)
DE (1)	DE69830660T2 (ja)
HU (1)	HUP0002645A3 (ja)
ID (1)	ID29298A (ja)
IL (2)	IL132133A0 (ja)
NO (1)	NO994613L (ja)
NZ (1)	NZ337969A (ja)
PL (1)	PL336326A1 (ja)
SK (1)	SK143199A3 (ja)
TR (1)	TR199902577T2 (ja)
TW (1)	TWI221771B (ja)
WO (1)	WO1998046245A1 (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8933032B2 (en)	1998-10-20	2015-01-13	Children's Hospital Medical Center	Surfactant protein D for the treatment of disorders associated with lung injury
US6613308B2 (en)	2000-09-19	2003-09-02	Advanced Inhalation Research, Inc.	Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en)	2000-09-19	2003-02-04	Advanced Inhalation Research, Inc.	Pulmonary delivery in treating disorders of the central nervous system
US6641542B2 (en) *	2001-04-30	2003-11-04	Medtronic, Inc.	Method and apparatus to detect and treat sleep respiratory events
AU2003217544A1 (en) *	2002-02-15	2003-09-09	Cns, Inc.	Throat spray
LT2630954T (lt)	2002-03-20	2017-01-25	Civitas Therapeutics, Inc.	Levodopos įvedimas į plaučius
US7647931B2 (en)	2002-12-30	2010-01-19	Quiescence Medical, Inc.	Stent for maintaining patency of a body region
US7992566B2 (en)	2002-12-30	2011-08-09	Quiescence Medical, Inc.	Apparatus and methods for treating sleep apnea
US7381222B2 (en)	2002-12-30	2008-06-03	Quiescence Medical, Inc.	Stent for maintaining patency of a body region
WO2007005672A2 (en) *	2005-06-30	2007-01-11	The Scripps Research Institute	Treatment and prevention of respiratory diseases and conditions
JP2007190278A (ja)	2006-01-20	2007-08-02	Omron Healthcare Co Ltd	呼吸訓練器
JP2007190275A (ja)	2006-01-20	2007-08-02	Omron Healthcare Co Ltd	呼吸訓練器
JP2007190277A (ja)	2006-01-20	2007-08-02	Omron Healthcare Co Ltd	呼吸訓練器および呼吸訓練プログラム
CA2641821C (en) *	2006-02-16	2017-10-10	Imthera Medical, Inc.	An rfid-based apparatus, system, and method for therapeutic treatment of a patient
US7748493B2 (en) *	2006-06-14	2010-07-06	Zmed Technologies, Inc.	Respiration stimulation
US7734350B2 (en) *	2006-06-14	2010-06-08	Zmed Technologies, Inc.	Respiration apparatus
WO2008006090A2 (en)	2006-07-06	2008-01-10	Quiescence Medical, Inc.	Apparatus and methods for treating sleep apnea
WO2009048581A1 (en) *	2007-10-09	2009-04-16	Imthera Medical, Inc.	System and method for neural stimulation
EP2230934B8 (en)	2007-12-14	2012-10-24	AeroDesigns, Inc	Delivering aerosolizable food products
AU2009302591B2 (en)	2008-10-09	2014-08-07	Imthera Medical, Inc.	Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue
CA2780096A1 (en)	2009-11-10	2011-05-19	Imthera Medical, Inc.	System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
WO2012025892A2 (en) *	2010-08-26	2012-03-01	Ben Gurion University Of The Negev Research And Development Authority	Apparatus and method for diagnosing obstructive sleep apnea
WO2012082791A2 (en)	2010-12-13	2012-06-21	Quiescence Medical, Inc.	Apparatus and methods for treating sleep apnea
US20120220531A1 (en)	2011-02-04	2012-08-30	Cincinnati Children's Hospital Medical Center	Surfactant protein d for the treatment of disorders associated with lung injury
US10265013B2 (en)	2013-09-06	2019-04-23	Somnology, Inc.	System and method for sleep disorder diagnosis and treatment
US10265014B2 (en)	2013-09-06	2019-04-23	Somnology, Inc.	System and method for sleep disorder diagnosis and treatment
CN105123926A (zh) *	2015-07-30	2015-12-09	安徽人人福豆业有限公司	一种疏肝理气豆渣发酵乳及其制备方法
CN105053191A (zh) *	2015-07-30	2015-11-18	安徽人人福豆业有限公司	一种消食木瓜豆渣发酵乳及其制备方法
CN104982527A (zh) *	2015-07-30	2015-10-21	安徽人人福豆业有限公司	一种安神豆渣发酵乳及其制备方法
CN105053192A (zh) *	2015-07-30	2015-11-18	安徽人人福豆业有限公司	一种椰香补肾豆渣发酵乳及其制备方法
CN105053196A (zh) *	2015-07-30	2015-11-18	安徽人人福豆业有限公司	一种风味草莓豆渣发酵乳及其制备方法
CN105010535A (zh) *	2015-07-30	2015-11-04	安徽人人福豆业有限公司	一种银耳豆渣发酵乳及其制备方法
CN105123927A (zh) *	2015-07-30	2015-12-09	安徽人人福豆业有限公司	一种芦荟健胃豆渣发酵乳及其制备方法
CN105053197A (zh) *	2015-07-30	2015-11-18	安徽人人福豆业有限公司	一种温中补血豆渣发酵乳及其制备方法
CN104996566A (zh) *	2015-07-30	2015-10-28	安徽人人福豆业有限公司	一种清肺酒香豆渣发酵乳及其制备方法
CN105053194A (zh) *	2015-07-30	2015-11-18	安徽人人福豆业有限公司	一种清热通络豆渣发酵乳及其制备方法
CN105104535A (zh) *	2015-07-30	2015-12-02	安徽人人福豆业有限公司	一种养颜豆渣发酵乳及其制备方法
CN105123928A (zh) *	2015-07-30	2015-12-09	安徽人人福豆业有限公司	一种润肠豆渣发酵乳及其制备方法
CN105053195A (zh) *	2015-07-30	2015-11-18	安徽人人福豆业有限公司	一种去火薄荷味豆渣发酵乳及其制备方法
WO2019018338A1 (en)	2017-07-17	2019-01-24	Northriver Pharm, LLC	NASAL COMPOSITION COMPRISING A MUCOADHESIVE POLYMER
CN111568853B (zh) *	2020-04-30	2023-07-28	杭州濡湜生物科技有限公司	一种新型肺部智能释药系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2520234A1 (fr) *	1982-01-28	1983-07-29	Gros Pierre	Composition destinee a la prevention du ronflement
US4826821A (en) *	1985-06-26	1989-05-02	The Regents Of The University Of California	Lung surfactant compositions
EP0273916A4 (en) *	1986-05-06	1989-11-30	Childrens Hosp Medical Center	LUNG HYDROPHOBES, PROTEIN ASSOCIATED TO A SURFACE ACTIVE MEDIUM OF 6000 DALTON MOLECULAR WEIGHT AND MULTIMEREOUS ITEMS.
JPS63208524A (ja) *	1987-02-25	1988-08-30	Nippon Oil & Fats Co Ltd	睡眠リズム改善剤
US5238920A (en) *	1989-08-22	1993-08-24	Abbott Laboratories	Pulmonary surfactant protein fragments
DE69125750D1 (de) *	1990-05-21	1997-05-28	Abbott Lab	Fettsäure-Oberflächenaktives-Lungenprotein Konjate
DE69332654T2 (de) *	1992-04-10	2003-09-25	Abbott Laboratories, Abbott Park	Fragmente eines oberflächenaktiven lungenproteins
US5569679A (en) *	1994-12-30	1996-10-29	Russell A. Krueger Pharmaceuticals, Inc.	Pharmacologic management of snoring
US6129934A (en) *	1995-06-07	2000-10-10	Ony, Inc.	Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
US5925334A (en) *	1997-08-27	1999-07-20	Rubin; Bruce K.	Use of surface active agents to promote mucus clearance

1997
- 1997-04-16 US US08/834,369 patent/US5958902A/en not_active Expired - Fee Related
1998
- 1998-04-02 CO CO98018668A patent/CO4940399A1/es unknown
- 1998-04-15 AR ARP980101739A patent/AR012221A1/es unknown
- 1998-04-15 TW TW087105709A patent/TWI221771B/zh not_active IP Right Cessation
- 1998-04-16 TR TR1999/02577T patent/TR199902577T2/xx unknown
- 1998-04-16 IL IL13213398A patent/IL132133A0/xx unknown
- 1998-04-16 WO PCT/US1998/007735 patent/WO1998046245A1/en not_active Ceased
- 1998-04-16 CN CN98804244A patent/CN1252727A/zh active Pending
- 1998-04-16 AU AU69755/98A patent/AU722866B2/en not_active Ceased
- 1998-04-16 JP JP54431498A patent/JP2001507364A/ja not_active Ceased
- 1998-04-16 DE DE69830660T patent/DE69830660T2/de not_active Expired - Fee Related
- 1998-04-16 BR BR9809090-9A patent/BR9809090A/pt not_active Application Discontinuation
- 1998-04-16 PL PL98336326A patent/PL336326A1/xx unknown
- 1998-04-16 SK SK1431-99A patent/SK143199A3/sk unknown
- 1998-04-16 HU HU0002645A patent/HUP0002645A3/hu unknown
- 1998-04-16 EP EP98915618A patent/EP1009411B1/en not_active Expired - Lifetime
- 1998-04-16 ID IDW991220A patent/ID29298A/id unknown
- 1998-04-16 AT AT98915618T patent/ATE298241T1/de not_active IP Right Cessation
- 1998-04-16 NZ NZ337969A patent/NZ337969A/en unknown
- 1998-04-16 CA CA002285574A patent/CA2285574C/en not_active Expired - Fee Related
- 1998-04-16 KR KR10-1999-7009471A patent/KR100381643B1/ko not_active Expired - Fee Related
1999
- 1999-05-17 US US09/313,110 patent/US6329352B1/en not_active Expired - Fee Related
- 1999-09-23 NO NO19994613A patent/NO994613L/no not_active Application Discontinuation
- 1999-09-29 IL IL132133A patent/IL132133A/en not_active IP Right Cessation
- 1999-10-12 BG BG103800A patent/BG103800A/xx unknown
2001
- 2001-12-10 US US10/016,474 patent/US20020099033A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR9809090A (pt)	2002-12-03
PL336326A1 (en)	2000-06-19
HUP0002645A2 (hu)	2001-06-28
IL132133A0 (en)	2001-03-19
AU6975598A (en)	1998-11-11
NO994613L (no)	1999-10-28
US20020099033A1 (en)	2002-07-25
TWI221771B (en)	2004-10-11
EP1009411A1 (en)	2000-06-21
DE69830660D1 (de)	2005-07-28
KR20010006384A (ko)	2001-01-26
AU722866B2 (en)	2000-08-10
TR199902577T2 (xx)	2000-02-21
CN1252727A (zh)	2000-05-10
ATE298241T1 (de)	2005-07-15
CA2285574A1 (en)	1998-10-22
CO4940399A1 (es)	2000-07-24
JP2001507364A (ja)	2001-06-05
IL132133A (en)	2008-12-29
AR012221A1 (es)	2000-09-27
US6329352B1 (en)	2001-12-11
HUP0002645A3 (en)	2002-12-28
EP1009411A4 (en)	2002-10-09
NZ337969A (en)	2001-12-21
KR100381643B1 (ko)	2003-04-26
HK1026141A1 (en)	2000-12-08
EP1009411B1 (en)	2005-06-22
NO994613D0 (no)	1999-09-23
CA2285574C (en)	2007-11-13
US5958902A (en)	1999-09-28
DE69830660T2 (de)	2006-05-04
WO1998046245A1 (en)	1998-10-22
ID29298A (id)	2001-08-16
BG103800A (en)	2000-03-31

Publication	Publication Date	Title
SK143199A3 (en)	2001-01-18	Pharmaceutical composition for treating sleep apnea, lung alveolar surfactant, phospholipid, use thereof and device for treating sleep apnea
JP3830158B2 (ja)	2006-10-04	禁煙補助組成物
BG105889A (bg)	2002-04-30	Използване на ксенон за лечение на невроинтоксикации
US9861647B2 (en)	2018-01-09	Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US5569679A (en)	1996-10-29	Pharmacologic management of snoring
US20030053956A1 (en)	2003-03-20	Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing
JP4173538B2 (ja)	2008-10-29	痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与
CA2408633C (en)	2004-07-20	Management of snoring by oral administration of dimethyl sulfone
Tierney et al.	1989	Obstructive sleep apnoea
CA2701388C (en)	2015-06-23	Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
CZ361199A3 (cs)	2000-02-16	Způsob a zařízení k léčbě spánkové apno
US20060210482A1 (en)	2006-09-21	Chemical composition and method for cold and sinus relief
HK1026141B (en)	2005-08-26	Treatment of sleep apnea
Berman et al.	1992	Sedation and analgesia
AU2002247032A1 (en)	2002-08-06	Alkyl aryl polyether alcohol polymers for improvement of nasal breathing